Radiopharmaceutical developers highlighted program progression and pipeline strategy in BIO-Europe presentations, focusing on optimizing therapeutic ratios by increasing tumor absorbed dose while reducing exposure to normal organs. Blue Earth Therapeutics described an ongoing Phase 2 prostate-specific membrane antigen program, with an alpha-emitting variant in Phase 1 and preclinical work on DNA-damage-targeting agents. The presentations reflect how radioligand companies are competing on both pharmacology and manufacturing/process robustness, particularly around dose delivery and lesion localization metrics. For investors and partners, the updates provide a snapshot of how radiopharmaceutical portfolios are being shaped toward multi-modal targeting strategies across prostate cancer lines and beyond.